NewAmsterdam’s cholesterol-lowering therapy shows Alzheimer’s promise

Data ReadoutpositiveobicetrapibPositive

AI Analysis

Summary

NewAmsterdam's obicetrapib, a cholesterol-lowering therapy, demonstrated positive results by reducing p-tau217 levels, an Alzheimer's biomarker, in patients with certain cardiovascular disease types.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Obicetrapib diminished levels of p-tau217, an Alzheimer's biomarker, in patients with certain types of CVD

Importance:6/10

Sentiment:

0.60

Alzheimer's diseasebiomarker reductioncardiovascular diseasecholesterol-lowering

Related Companies

$NAMSW

Read the original article

Published by Clinical Trials Arena on July 13, 2026 2:35 PM

Read Original